Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of MPC EV on myotubes

ABSTRACT: The effect of MPC EV on myotubes

PROVIDER: PRJNA641856 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12090414_1.fastq.gz	Fastqsanger.gz
	SRR12090414_2.fastq.gz	Fastqsanger.gz
	SRR12090415_1.fastq.gz	Fastqsanger.gz
	SRR12090415_2.fastq.gz	Fastqsanger.gz
	SRR12090416_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

MPC EVs onto Myotubes

Project description:MPC EVs onto Myotubes

| PRJNA641859 | ENA

MPC EV miRNA Microarray

Project description:MPC EV miRNA Microarray

| PRJNA641860 | ENA

The effect of MPC EV on myotubes

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-12-01 | GSE153249 | GEO

MPC EVs onto Myotubes

Project description:Extracellular vesicles (EVs) from proliferating primary myogenic progenitor cells (MPCs) were incubated on myotubes for 12 and 24 hours

2020-12-01 | GSE153248 | GEO

Effect of mycophenolic acid on MPC-1 murine podocytes

Project description:Effect of mycophenolic acid on MPC-1 murine podocytes

| PRJEB52911 | ENA

MPC EV miRNA Microarray

Project description:Extracellular vesicles (Evs) from proliferating myogenic progenitor cells (MPCs) were isolated and RNA was profiled via miRNA microarray

2020-12-01 | GSE153247 | GEO

Glucocorticoid receptor (GR) target genes in C2C12 myotubes

Project description:Analysis of C2C12 myotubes treated with dexamethasone (Dex) for 6 or 24 hours. Dex is a synthetic glucorticoid receptor agonist. Results provide insight to the effect of glucocorticoids on myotubes.

2011-04-25 | GSE28840 | GEO

Extracellular vesicle (EV) miRNome profiling in hiPSC-cardiomyocyte differentiation reveals a stemness-maintenance miRNA cluster driving hiPSC-EV bioactivity

Project description:Extracellular Vesicles (EV) are an attractive therapy to boost cardiac regeneration. Nevertheless, identification of EV and corresponding cell platform(s) suitable for therapeutic application, is still a challenge. Here, we isolated EV from key stages of the human induced pluripotent stem cell-cardiomyocyte (hiPSC-CM) differentiation and maturation, i.e., from hiPSC (hiPSC-EV), cardiac progenitors (CPC-EV), immature (CMi-EV) and mature (CMm-EV) cardiomyocytes, with the aim of identifying a promising cell biofactory for EV production, and pinpoint the genetic signatures of bioactive EV. EV were characterized in terms of expression of specific markers, yield, and size. Bioactivity was assessed in human umbilical vein endothelial cells (HUVEC) and hiPSC-CM. Small RNA-Seq was performed to identify the differentially expressed miRNA in the four EV groups. Bioactivity assays showed increased tube formation and migration in HUVEC treated with hiPSC-EV compared to EV from committed cell populations. hiPSC-EV also significantly increased hiPSC-CM proliferation. Global miRNA expression profiles corroborated an EV-miRNA pattern indicative of stem cell to cardiomyocyte specification. A stemness maintenance miRNA cluster upregulated in hiPSC-EV was found to target the PTEN/PI3K/AKT pathway. Moreover, hiPSC-EV treatment mediated PTEN suppression and increased AKT phosphorylation. Overall, our findings validate hiPSC as suitable cell biofactories for EV production for cardiac regenerative applications.

2022-06-01 | GSE179323 | GEO

Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomic and transcriptomic evolution

Project description:Extracellular vesicles (EVs) secreted by tumors are abundant in plasma, but their potential for multi-omic profiling remains widely unexplored. Here, we pursued next-generation sequencing of circulating EV-DNA and EV-RNA in metastatic prostate cancer (mPC), using a range of in-vitro and in-vivo models, validating our findings in 35 mPC patients with longitudinal samples collected during androgen receptor signaling inhibitor (ARSI) therapy. EV-DNA copy-number (CN) profiles matched same-patient biopsies and ctDNA (p<0.001) and EV-DNA tumor fraction (TF) associated with shorter time to progression. We developed a novel approach for studying mRNA in circulating EVs (RExCuE), showing high correlation between EV-RNA and tumor biopsies (r>0.7, p<0.001). EV-RNAseq signatures at 4 weeks of therapy associated with clinical responses. Last, we derived a specific signature of ARSI response in EV-RNA in vivo that predicted response to therapy. In conclusion, EV profiling enables the study of mPC evolution at transcriptomics level in liquid biopsies.

2024-06-30 | GSE221709 | GEO

Human lung MPC

Project description:A comparison of gene expression between control versus IPF human lung MPC using human Affy 1.0st chips. This work was funded by grants to S.M. Majka from the NIH R01HL091105 and NIH R01HL11659701. Additional funding was also provided by PPG-5P01HL108800-04 (PI:J. Loyd). Experiments were performed using the University of Colorado Cancer Center Microarray core (NCI P30 CA 46934-14). The project was supported in part by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06.

2017-03-23 | GSE94060 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data